Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study

Απλή σελίδα τεκμηρίου
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorBamias, A.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorXiros, N.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorVarthalitis, I.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:03:22Z
dc.date.available2015-11-24T19:03:22Z
dc.identifier.issn0344-5704-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19891
dc.rightsDefault Licence-
dc.subject*Adenocarcinoma/drug therapy/mortality/secondaryen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectCamptothecin/administration & dosage/adverse effects/analogs &en
dc.subjectderivatives/therapeutic useen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasms, Unknown Primary/*drug therapy/mortalityen
dc.subjectOrganoplatinum Compounds/administration & dosage/adverse effects/therapeutic useen
dc.titleMulticenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group studyen
heal.abstractBACKGROUND: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan-oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas. METHODS: This was a multicenter phase-II trial. Protocol treatment consisted of oxaliplatin 80 mg/m(2) followed by irinotecan 160 mg/m(2) administered every 3 weeks. The primary end points were response rate and toxicity, and secondary end points were time to progression and survival. RESULTS: Forty-seven patients with liver, bone or multiple visceral metastases entered into the trial and received a median 6 chemotherapy cycles (1-11). The regimen was very well tolerated with one febrile neutropenia case and six cases with diarrhea grade 3 (16%). In intent-to-treat analysis the tumor response rate was 13% (95% CI = 4.8-25.7%) and 12 patients (27%, 95%CI 13.9-40.4%) had at least 4 months' duration of disease stabilization. The median time to progression was 2.7 months and the median survival was 9.5 months, with 40% of patients alive at 1 year. CONCLUSIONS: The IROX regimen demonstrated similar efficacy and a favorable toxicity profile compared to other more toxic chemotherapy combinations in patients with poor-prognosis CUP.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1007/s00280-007-0604-7-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17901952-
heal.identifier.secondaryhttp://www.springerlink.com/content/n82v1wj2u2l46925/fulltext.pdf-
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ